Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Effaclar AI
- Development stage
- Unknown
- Lead developer
- La Roche-Posay
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Effaclar AI is a targeted topical spot treatment formulated for oily and acne-prone skin to accelerate the resorption of imperfections and prevent residual marks. Developed by La Roche-Posay, the formulation centers on a combination of **capryloyl salicylic acid (LHA)**, a lipophilic derivative of salicylic acid that provides precise micro-exfoliation to unclog pores, and **niacinamide**, which exerts anti-inflammatory effects to soothe redness. Additionally, it contains **piroctone olamine** and **glycacil** to inhibit bacterial proliferation (specifically *Cutibacterium acnes*). The product is designed for localized application on individual blemishes to reduce inflammation and promote skin recovery.
- Brand names
- Effaclar AIEffaclar A.I.
- Other names
- La Roche-Posay Effaclar AIEffaclar AI Targeted Breakout Corrector
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))PARP1 (Poly (adp-ribose) polymerase 1)
Beyond the preview
Go deeper on Effaclar AI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Effaclar AI.